TY - JOUR
T1 - SUDOSCAN, an Innovative, Simple and Non-Invasive Medical Device for Assessing Sudomotor Function
AU - Gavan, Dana Elena
AU - Gavan, Alexandru
AU - Bondor, Cosmina Ioana
AU - Florea, Bogdan
AU - Bowling, Frank Lee
AU - Inceu, Georgeta Victoria
AU - Colobatiu, Liora
N1 - Funding Information:
This research was funded by a grant of the Executive Agency for Higher Education, Research, Development and Innovation Funding, Romania, Grant no. PD 100/2020, Project ID PN-III-P1-1.1-PD-2019-0721, within PNCDI III.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/10/6
Y1 - 2022/10/6
N2 - Diabetic autonomic neuropathy is probably the most undiagnosed but serious complication of diabetes. The main objectives were to assess the prevalence of peripheral and autonomic neuropathy in a population of diabetic patients, analyze it in a real-life outpatient unit scenario and determine the feasibility of performing SUDOSCAN tests together with widely used tests for neuropathy. A total of 33 patients were included in the study. Different scoring systems (the Toronto Clinical Neuropathy Score-TCNS; the Neuropathy Disability Score-NDS; and the Neuropathy Symptom Score-NSS) were applied to record diabetic neuropathy (DN), while the SUDOSCAN medical device was used to assess sudomotor function, detect diabetic autonomic neuropathy and screen for cardiac autonomic neuropathy (CAN). Fifteen (45.5%) patients had sudomotor dysfunction. The SUDOSCAN CAN risk score was positively correlated with the hands' electrochemical sweat conductance (ESC), diastolic blood pressure (DBP), the level of the glycated hemoglobin, as well as with the TCNS, NDS and NSS. Performing SUDOSCAN tests together with other tests for DN proved to be a feasible approach that could be used in daily clinical practice in order to screen for DN, as well as for the early screening of CAN, before more complex and time-consuming tests.
AB - Diabetic autonomic neuropathy is probably the most undiagnosed but serious complication of diabetes. The main objectives were to assess the prevalence of peripheral and autonomic neuropathy in a population of diabetic patients, analyze it in a real-life outpatient unit scenario and determine the feasibility of performing SUDOSCAN tests together with widely used tests for neuropathy. A total of 33 patients were included in the study. Different scoring systems (the Toronto Clinical Neuropathy Score-TCNS; the Neuropathy Disability Score-NDS; and the Neuropathy Symptom Score-NSS) were applied to record diabetic neuropathy (DN), while the SUDOSCAN medical device was used to assess sudomotor function, detect diabetic autonomic neuropathy and screen for cardiac autonomic neuropathy (CAN). Fifteen (45.5%) patients had sudomotor dysfunction. The SUDOSCAN CAN risk score was positively correlated with the hands' electrochemical sweat conductance (ESC), diastolic blood pressure (DBP), the level of the glycated hemoglobin, as well as with the TCNS, NDS and NSS. Performing SUDOSCAN tests together with other tests for DN proved to be a feasible approach that could be used in daily clinical practice in order to screen for DN, as well as for the early screening of CAN, before more complex and time-consuming tests.
KW - Autonomic Nervous System
KW - Diabetic Neuropathies/diagnosis
KW - Galvanic Skin Response
KW - Glycated Hemoglobin
KW - Humans
KW - Naphthalenesulfonates
KW - sudomotor function
KW - SUDOSCAN
KW - cardiac autonomic neuropathy
KW - diabetes mellitus
KW - medical device
U2 - 10.3390/s22197571
DO - 10.3390/s22197571
M3 - Article
C2 - 36236669
SN - 1424-8220
VL - 22
JO - Sensors (Basel, Switzerland)
JF - Sensors (Basel, Switzerland)
IS - 19
M1 - 7571
ER -
